CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Tempus to buy cancer test-maker Personalis for $1.5B

Positive
AI Analysis

Summary

Tempus AI has announced a $1.5 billion acquisition of Personalis, a cancer test-maker, reflecting growing industry interest in blood-based cancer diagnostic solutions.

Importance:7/10
Sentiment:
0.60
M&Aacquisitioncancer testingblood-based testsoncology
Related Companies

Read the original article

Published by BioPharma Dive on July 20, 2026 6:38 PM

Read Original